Interestingly, CoDa Therapeutics Inc., USA and New Zealand, has Cx channel modulators in clinical development (chronic skin wounds, ocular disease), e.g., an antisense oligodeoxynucleotide (Nexagon®) that transiently downregulates Cx43 protein expression (e.g., thermoreversible gel for eye injuries [224]), an extracellular acting Cx43 peptidomimetic that can be delivered locally or systemically (PeptagonTM [225]) (Peptide5) and a small molecule for systemic or oral delivery (HCB1019). Here, GJA1 is linked to eye injury.